On October 19, 2025, the eight-day "Connecting Eurasia · Building the Future" event, where Chengdu industrial enterprises went to Germany and France to explore markets and promote exchanges, concluded successfully. As a key part of the "Chengdu-Made · Globally Sold" series of activities, this visit brought together a delegation of over 40 high-quality Chengdu-based enterprises. Through various forms such as economic and trade negotiations, thematic seminars, and on-site inspections, it effectively built a cooperation bridge between Chengdu and the European industrial community, promoting in-depth collaboration between the two sides in the fields of electronic information, equipment manufacturing, medical and health care, new materials, green food, and advanced energy.
Mr. Zhang Qiang, Chairman of Sichuan Xieli Pharmaceutical Co., Ltd., led the company's team to participate in this visit as part of the delegation. Through a series of practical measures including product exhibitions, thematic seminars, project signings, and on-site inspections, the team actively expanded European market resources, helped "Chengdu-Made" pharmaceutical products better integrate into the European supply chain system, and demonstrated the international competitiveness of Chengdu's pharmaceutical enterprises.
During the stay in Germany, the delegation gained in-depth insights into cutting-edge smart manufacturing experiences. They attended lectures by professors from the Technical University of Munich on "The Background and Strategy of German Industry 4.0", and visited the Audi factory and Siemens Amberg factory. By delving into the "German code" of digital transformation and quality control, the delegation provided important references for Chengdu enterprises to advance their intelligent transformation.
As a key part of the German itinerary, the "2025 Chengdu-Munich Industrial Cooperation and Matching Fair" was successfully held in Munich, Germany on October 14 (local time). Senior officials from the German state of Bavaria, representatives of the Chinese Consulate General in Munich, and elites from the German business community, including Fortune 500 companies such as Siemens, BMW, and Bosch, gathered together to explore cooperation opportunities.
At the fair, Xieli Pharm and German Midas Pharma signed a strategic cooperation agreement in two major areas: high-quality API (Active Pharmaceutical Ingredient) supply and internationalization of pharmaceutical preparations. This means that relying on a quality system that meets EU standards, Xieli Pharmaceutical will leverage its industrial chain synergy and customized development capabilities to provide stable and reliable APIs and pharmaceutical preparations for European pharmaceutical enterprises, opening a key channel for "Chengdu-Made" pharmaceuticals to enter the core European market.
During the French itinerary, the delegation focused on "Green transformation and global layout". They participated in the "Invest in China · Invest in the Future" conference held by the Paris Chamber of Commerce, conducted one-on-one in-depth negotiations with more than 60 French enterprises, and visited leading companies such as Schneider Electric and Total Energies. By systematically learning about green production standards and the experience of building an international logistics network, the delegation accumulated practical references for the green and international development of Chengdu's pharmaceutical industry.
Summarizing the visit, Mr. Zhang Qiang, Chairman of Xieli Pharmaceutical, stated: "The global expansion of Chengdu's pharmaceuticals is a common goal of the entire industrial chain. We should not only be pioneers but also bridge-builders." This trip to Germany and France not only enabled the company to accurately connect with high-quality European resources and expand cooperation space but also injected new impetus into the overall global expansion of Chengdu's bio-pharmaceutical industrial chain.
In the future, taking this visit as an opportunity, Xieli Pharmaceutical will continue to deepen multi-level cooperation with the European market, promote the international export of a full range of products from APIs to pharmaceutical preparations, drive more Chengdu-based pharmaceutical enterprises to enter the international market, and continuously enhance the position and influence of "Chengdu-Made" in the international pharmaceutical industrial chain.
